At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...

This was the stock's fourth consecutive day of losses.

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...